Overview

* Amphastar Q3 revenue of $191.8 mln beats analyst expectations

* Adjusted EPS for Q3 at $0.93, surpassing consensus estimates

* Company received FDA approval and launched iron sucrose injection

Outlook

* Company expects strategic pipeline expansion to drive long-term growth

* Amphastar anticipates revenue growth from new iron sucrose injection

* Company sees growth potential in novel peptides targeting oncology and ophthalmology

Result Drivers

* BAQSIMI SALES - Double-digit growth in BAQSIMI sales due to increased unit volumes from expanded marketing efforts in the U.S.

* IRON SUCROSE LAUNCH - Launch of iron sucrose injection contributed to revenue growth, expanding patient access to affordable therapies

* LICENSING AGREEMENT - Strategic licensing agreement with Nanjing Anji Biotechnology to develop novel peptides for oncology and ophthalmology markets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $191.84 $187 mln

Revenue mln (6

Analysts

)

Q3 Beat $0.93 $0.85 (6

Adjusted Analysts

EPS )

Q3 EPS $0.37

Q3 Beat $44.70 $41.90

Adjusted mln mln (5

Net Analysts

Income )

Q3 Net $17.35

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Amphastar Pharmaceuticals Inc ( AMPH ) is $35.00, about 27.7% above its November 5 closing price of $25.31

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)